Skip to main content

Table 2 Plasma ACTH and lactate, serum triglyceride, cortisol and blood K+, Na+ and BE concentrations

From: Changes in energy metabolism, and levels of stress-related hormones and electrolytes in horses after intravenous administration of romifidine and the peripheral α-2 adrenoceptor antagonist vatinoxan

Analyte

Treatment

Baseline

T15

T30

T60

T120

ACTH

ROM

16.8 (± 3.83)

32.3 (± 22.4)

25.0 (± 12.5)

18.7 (± 7.66)

44.7 (± 62.4)

ROM + V

19.4 (± 11.1)

28.5 (± 12.4)

21.6 (± 8.39)

21.4 (± 13.2)

19.1 (± 11.1)

V

17.3 (± 6.53)

32.2* (± 6.66)

29.0* (± 5.71)

23.0 (± 5.68)

16.1 (± 5.68)

Lactate

ROM

0.60 (± 0.30)

0.61 (± 0.17)

0.63 (± 0.24)

0.49 (± 0.11)

0.41 (± 0.24)

ROM + V

0.58 (± 0.29)

0.69 (± 0.24)

0.70 (± 0.27)

0.71 (± 0.24)

0.56 (± 0.17)

V

0.50 (± 0.59)

0.55 (± 0.35)

0.55 (± 0.33)

0.61 (± 0.30)

0.70 (± 0.35)

Triglycerides

ROM

0.30 (± 0.10)

0.36 (± 0.13)

0.37 (± 0.13)

0.36 (± 0.13)

0.27 (± 0.07)

ROM + V

0.27 (± 0.03)

0.30 (± 0.06)

0.30 (± 0.09)

0.29 (± 0.12)

0.24 (± 0.12)

V

0.28 (± 0.08)

0.32 (± 0.09)

0.33 (± 0.11)

0.30 (± 0.10)

0.23 (± 0.11)

Cortisol

ROM

59.0 (± 13.9)

120* (± 34.7)

106 (± 37.6)

86.6 (± 35.4)

113 (± 51.7)

ROM + V

51.9 (± 16.1)

107* (± 24.7)

84.1 (± 23.1)

76.5 (± 29.0)

66.3 (± 26.5)

V

61.2 (± 14.7)

131* (± 34.2)

120* (± 30.4)

102 (± 23.5)

79.4 (± 32.7)

Analyte

Treatment

Baseline

T5

T15

T30

T60

BE

ROM

4.00 (± 0.54)

4.04 (± 0.95)

4.47 (± 0.47)

4.76 (± 0.79)

5.74* (± 0.88)

ROM + V

4.46 (± 1.43)

4.19 (± 1.32)

4.31 (± 1.55)

4.84 (± 1.30)

5.41 (± 1.06)

V

3.86 (± 0.78)

3.63 (± 0.87)

3.96 (± 0.96)

4.19 (± 0.66)

5.24* (± 0.57)

K+

ROM

4.30 (± 0.26)

4.16 (± 0.28)

4.09* (± 0.28)

4.16 (± 0.30)

4.17 (± 0.27)

ROM + V

4.20 (± 0.29)

4.11 (± 0.40)

3.87*,$ (± 0.28)

3.91 (± 0.25)

3.84* (± 0.27)

V

4.44 (± 0.36)

4.39 (± 0.28)

4.30$ (± 0.31)

4.21 (± 0.36)

3.94* (± 0.31)

  1. Means (± SD) of plasma ACTH (pg/mL), plasma lactate (mmol/L), serum triglyceride (mmol/L), serum cortisol (nmol/mL) and venous blood K+and BE (mmol/L) concentrations of seven horses. The horses received romifidine (ROM, 80 μg/kg IV), ROM with vatinoxan (ROM + V, 80 μg/kg + 200 μg/kg IV) and vatinoxan (V, 200 μg/kg IV) at T0
  2. * Significantly different (P < 0.05) from baseline (T0)
  3. $ Significant difference between treatments